Boothbay Fund Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Boothbay Fund Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-37,000	Closed	-$1.41M	–	2625
2022 Q4	$1.41M	Buy	+37,000	New	+$1.27M	0.03%	751
2022 Q2	–	Sell	-78,600	Closed	-$2.58M	–	2811
2022 Q1	$2.58M	Buy	78,600 +68,500	+678%	+$2.03M	0.06%	469
2021 Q4	$266K	Sell	10,100 -37,500	-79%	-$2.9M	0.01%	1323
2021 Q3	$4.79M	Buy	47,600 +27,800	+140%	+$3.26M	0.13%	173
2021 Q2	$2.8M	Buy	19,800 +19,680	+16,400%	+$2.22M	0.09%	267
2021 Q1	$1.2M	Sell	120 -51	-30%	-$5.95K	0.04%	511
2020 Q4	$2.11M	Buy	171 +112	+190%	+$14.7K	0.08%	252
2020 Q3	$575K	Sell	59 -46	-44%	-$5.75K	0.03%	608
2020 Q2	$1.64M	Sell	105 -13	-11%	-$1.98K	0.11%	245
2020 Q1	$1.7M	Buy	+118	New	+$22.8K	0.14%	179
2019 Q4	–	Sell	-59	Closed	-$474K	–	1046
2019 Q3	$474K	Hold	59	–	–	0.04%	473
2019 Q2	$557K	Hold	59	–	–	0.05%	387
2019 Q1	$504K	Buy	+59	New	+$4.9K	0.05%	374

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's RETA Position: Q2 2023 in Review

Boothbay Fund Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 16,154 shares — an estimated $1.53M sold.

Boothbay Fund Management first reported a position in RETA in Q4 2020 and held it in 3 quarters. The position peaked at $1.47M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Boothbay Fund Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 16,154 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.53M.
Boothbay Fund Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 3 quarters.
Boothbay Fund Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.47M in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.